{"ticker": {"uuid": "13329539-a11a-4f6e-acd2-e0ab10d746a9", "symbol": "NBIX", "name": "Neurocrine Biosciences Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and Ball", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxQVmNmU1ZxR3NqRTJyaWRyZ2xRdmh6LUVSYTgwa3I2MGRzQmZ2TC01WVZuRE9ZcWg2YmozUFZrWkRIdVpZeFpGRkdVaVBBam9QcS01eVN2OVpzRVRrZ3duM2FfTVA2Yk1zUUg4cVhpNlIxdEZMUVRXQlpmaEl3ZzlmeFphTFUwa2JzSFFJTFhSY0M4b1VBZmFxR01Bd0YxUDFiVWEzbm9VcjNkcTBwbDcwS0NmZ2dVSGMyeFY0UkhvaUVCM2hDT3RObXM3VHRaay05Z2ZzajJ3ZG9LRlNYTTQ1cmdISTJIQTBoaHJrV2oxXzQtZw?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-16T09:26:25+00:00", "published_display": "16 Jul 2026 09:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences (NASDAQ:NBIX) Fits the Growth at a Reasonable Price Mold of Peter Lynch Screening", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxNcjB5TkN6czEtZUtJcWhydlRPaWlpVklUUnI2ZmpDclFGejVhR3BYRnhpZDhWWkMxeTNhOV9TQzRfREZxcEdoeGtWcVFNZmtwR25zdERjXzRHWTVMZ2pKcXB6bTgyS0NCcWQ3SGpIUHkxTjlQWHRVb0Qzc0NXZTJEMnNsVU9EWG5WcXl1Y3NPcExSLXNfVnhsTmxzS1BmbG5jcVZyakttUDNsNDhmaDJQTzNhRGptcTdxN0RpWE84TWhOTjdyLWctZVdwcHo0X1dCNXZOLVUtSEdFMWpRRVdEM2NBellqam1h?oc=5", "source_name": "ChartMill", "published_at": "2026-07-16T09:00:29+00:00", "published_display": "16 Jul 2026 09:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Securities Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $199", "summary": "BofA Securities has reiterated its Buy rating on Neurocrine Biosciences (NBIX.US) and set a price target of $199. This indicates a positive outlook from the analyst firm regarding the company's future stock performance.", "url": "https://www.moomoo.com/news/post/73008003/bofa-securities-maintains-neurocrine-biosciences-nbixus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-07-16T06:41:37", "published_display": "16 Jul 2026 06:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Neurocrine (NBIX) Run Higher on Rising Earnings Estimates?", "summary": "Neurocrine Biosciences (NBIX) shows strong potential for continued stock growth due to its remarkably improving earnings outlook. Analysts are consistently raising earnings estimates for the biopharmaceutical company, indicating growing optimism. This positive trend in revisions,", "url": "https://finance.yahoo.com/markets/stocks/articles/neurocrine-nbix-run-higher-rising-162002030.html", "source_name": "Market source", "published_at": "2026-07-14T16:13:39", "published_display": "14 Jul 2026 16:13", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Neurocrine Biosciences Inc For: 13 July By Investing.com", "summary": "This article from Investing.com is a standard Form 4 filing for Neurocrine Biosciences Inc (NBIX) as of July 13. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders.", "url": "https://ng.investing.com/news/stock-market-news/form-4-neurocrine-biosciences-inc-for-13-july-93CH-2597537", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T01:11:10", "published_display": "14 Jul 2026 01:11", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences chief legal officer sells $1.79m in stock By Investing.com", "summary": "Darin Lippoldt, Chief Legal Officer at Neurocrine Biosciences (NASDAQ:NBIX), sold 10,000 shares for $1.79 million and simultaneously acquired 10,000 shares for $814,900 through option exercise on July 9, 2026. This transaction occurred while the stock was near its 52-week high, a", "url": "https://ng.investing.com/news/stock-market-news/neurocrine-biosciences-chief-legal-officer-sells-179m-in-stock-93CH-2597515", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T21:32:00", "published_display": "13 Jul 2026 21:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity", "summary": "Neurocrine Biosciences Inc.'s Chief Legal Officer, Darin Lippoldt, reported an open-market sale of 10,000 shares of common stock at a weighted average price of $179.6014 per share, executed under a pre-arranged Rule 10b5-1 trading plan. On the same day, Lippoldt exercised non-qua", "url": "https://www.stocktitan.net/sec-filings/NBIX/form-4-neurocrine-biosciences-inc-insider-trading-activity-d9d7f3ed5f97.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:11:10", "published_display": "13 Jul 2026 21:11", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences chief legal officer sells $1.79m in stock", "summary": "Darin Lippoldt, Chief Legal Officer at Neurocrine Biosciences, sold 10,000 shares of common stock for $1.79 million on July 9, 2026, through a pre-planned trading arrangement, while the stock trades near its 52-week high. Prior to this sale, Lippoldt acquired 10,000 shares by exe", "url": "https://www.investing.com/news/insider-trading-news/neurocrine-biosciences-chief-legal-officer-sells-179m-in-stock-93CH-4789271", "source_name": "Investing.com", "published_at": "2026-07-13T20:13:39", "published_display": "13 Jul 2026 20:13", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences (NBIX) officer exercises options, sells 4,367 shares", "summary": "Neurocrine Biosciences' Chief Regulatory Officer, Ingrid Delaet, executed an options exercise and stock sale. She acquired 4,367 shares at $106.02 per share and simultaneously sold them at an average price of $181.02 per share through a pre-arranged Rule 10b5-1 trading plan. Foll", "url": "https://www.stocktitan.net/sec-filings/NBIX/form-4-neurocrine-biosciences-inc-insider-trading-activity-0c1848f39ffd.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:11:10", "published_display": "13 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist raises Neurocrine Bio stock price target on pipeline potential", "summary": "Truist Securities has increased its price target for Neurocrine Biosciences Inc. (NASDAQ: NBIX) shares to $200 from $155, maintaining a Buy rating, due to strong pipeline potential and expected Q2 2026 results beating expectations. The firm anticipates a fiscal year 2026 guidance", "url": "https://www.investing.com/news/analyst-ratings/truist-raises-neurocrine-bio-stock-price-target-on-pipeline-potential-93CH-4788462", "source_name": "Investing.com", "published_at": "2026-07-13T12:41:50", "published_display": "13 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Lifts Price Target on Neurocrine Biosciences to $185 From $176, Keeps Outperform Rating", "summary": "Wedbush has increased its price target for Neurocrine Biosciences (NBIX) shares to $185 from $176, while maintaining an Outperform rating. This adjustment reflects Wedbush's continued positive outlook on the company's prospects.", "url": "https://www.moomoo.com/news/post/72858445/wedbush-lifts-price-target-on-neurocrine-biosciences-to-185-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T12:11:10", "published_display": "13 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences Inc (NASDAQ:NBIX) Scores High in Affordable Growth Screen", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxORVNkaGx2VWJCUU01YmRXcGk1SVVLelNLSmxiU25SUUJfQWpFbDRYZ1VsYUZ4SDBXSFdOYVlubk1LT0F1UnU4Wm8zaHlCY29TUnktM09tR2MyY1JPaFpQRWd6R2RDTGdGUDliZkgyQThOa3F2a2Q2TVcwUXhONC0tNGp3VkFveTJmcE9CdXVGMUZoZVNXNUJnXzdlSW83ZWthYlEwdmg0LU83dDV4LVRNU3l3d1lJSnBveVVsT3c0WkJKNTcwNkkxWQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T09:20:27+00:00", "published_display": "11 Jul 2026 09:20", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences (NBIX) Posts Strong Q1 Results, Is More Upside Still Left?", "summary": "Neurocrine Biosciences (NBIX) reported strong Q1 2026 results with over US$800 million in net product sales, driven by INGREZZA, leading to significant institutional interest and a 37.41% share price return over 90 days. Despite this surge, Simply Wall St's narrative valuation su", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/neurocrine-biosciences-nbix-posts-strong-q1-results-is-more", "source_name": "Simply Wall Street", "published_at": "2026-07-11T08:11:10", "published_display": "11 Jul 2026 08:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEUROCRINE BIOSCIENCES INC (NBIX) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTFB4TWdGYmo5N01lVF9hc2tfcXFpWkNQZjExcXpxNGZyT0JJeHpEbF9GYnVIbjY0SmVsOVptSWNxSFduMHJJQy1CRzVfcFVrRE0wYW1zLXdPcWNlR1QxeWVSS0g2dEQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T00:20:41+00:00", "published_display": "11 Jul 2026 00:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] NEUROCRINE BIOSCIENCES INC SEC Filing", "summary": "Neurocrine Biosciences (NBIX) filed a Form 144 indicating an affiliate plans to sell 4,367 shares of common stock on 07/10/2026, valued at $788,461.85, connected to the exercise of stock options. This filing also details prior Rule 10b5-1 sales by Ingrid Delaet, including 8,433 s", "url": "https://www.stocktitan.net/sec-filings/NBIX/144-neurocrine-biosciences-inc-sec-filing-299576120862.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:41:03", "published_display": "10 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences Insider Sold Shares Worth $2,603,112, According to a Recent SEC Filing", "summary": "An insider at Neurocrine Biosciences recently sold shares totaling $2,603,112. This transaction was disclosed in a recent SEC filing, indicating significant insider selling activity.", "url": "https://www.moomoo.com/news/post/72764814/neurocrine-biosciences-insider-sold-shares-worth-2603112-according-to-a?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-10T19:39:21", "published_display": "10 Jul 2026 19:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNV1hvazEtOEtkeGFjQTN3Q0ZIcTJScV9lX0FqUk1aQVVrWjhXdXZiWFFlaXVSMVJpQnZPcksxQkE3azVDN0hsdDRobFF4dmxTRkw0U1F0U2lXd1M3MlVuQTVGMGxZOVhIcFJTeWRIRTIwT2tmQ1VfVHl4OUN4OWxTRFBHbDhGLUpzd2xKOFhfY3Z0VGtzVXdLQnQ1QQ?oc=5", "source_name": "Market source", "published_at": "2026-07-10T16:45:02+00:00", "published_display": "10 Jul 2026 16:45", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/neurocrine-shares-hit-highs-sales-155848153.html", "source_name": "FX Empire", "published_at": "2026-07-10T15:58:48+00:00", "published_display": "10 Jul 2026 15:58", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences (NBIX) Stock Looks Reasonable After Its 90% Run", "summary": "After a significant 90% return over the past five years, Neurocrine Biosciences (NBIX) appears to be trading near its fair value rather than offering a clear bargain. The stock's current P/E ratio of 26.8x is higher than the biotech industry average but aligns closely with its ta", "url": "https://www.sahmcapital.com/news/content/neurocrine-biosciences-nbix-stock-looks-reasonable-after-its-90-run-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T06:41:03", "published_display": "10 Jul 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Neurocrine\u2019s (NBIX) CRENESSITY Push Into Infants Just Recast Its Rare-Disease Strategy?", "summary": "Neurocrine Biosciences has launched a Phase 2 study for CRENESSITY in infants, signaling a strategic push into younger pediatric patients with congenital adrenal hyperplasia, a group with no approved therapies. While this move could broaden CRENESSITY\u2019s market, the company's fina", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/did-neurocrines-nbix-crenessity-push-into-infants-just-recas/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-10T02:39:36", "published_display": "10 Jul 2026 02:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences chief regulatory officer sells $2.6m stock By Investing.com", "summary": "Ingrid Delaet, Chief Regulatory Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), sold approximately $2.6 million worth of common stock between July 7 and July 9, 2026, following the exercise of stock options. The sales were conducted through a Rule 10b5-1 trading plan, with ", "url": "https://ca.investing.com/news/stock-market-news/neurocrine-biosciences-chief-regulatory-officer-sells-26m-stock-93CH-4728313", "source_name": "Investing.com Canada", "published_at": "2026-07-09T22:39:36", "published_display": "09 Jul 2026 22:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Neurocrine Biosciences Inc For: 9 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Neurocrine Biosciences Inc. with the filing date of July 9. Form 4s are SEC filings used to report changes in beneficial ownership of securities by company insiders. The article notes that Neurocrine Biosciences Inc. ", "url": "https://ca.investing.com/news/stock-market-news/form-4-neurocrine-biosciences-inc-for-9-july-93CH-4728315", "source_name": "Investing.com Canada", "published_at": "2026-07-09T22:39:35", "published_display": "09 Jul 2026 22:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine (NBIX) officer sells 14,571 shares under Rule 10b5-1 plan", "summary": "Ingrid Delaet, Neurocrine Biosciences' Chief Regulatory Officer, exercised stock options for 14,571 shares and subsequently sold them in open-market transactions between July 7-9, 2026. The sales, executed under a pre-arranged Rule 10b5-1 trading plan, netted approximately $2.60 ", "url": "https://www.stocktitan.net/sec-filings/NBIX/form-4-neurocrine-biosciences-inc-insider-trading-activity-ad93694159b9.html", "source_name": "Stock Titan", "published_at": "2026-07-09T22:39:35", "published_display": "09 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results", "summary": "Neurocrine Biosciences, Inc. announced its second quarter 2026 financial results conference call and webcast will take place on July 30, 2026, at 1:30 p.m. Pacific Time. The press release will be issued at 1:00 p.m. PT on the same day. Details for dial-in and webcast access are p", "url": "https://www.aspendailynews.com/online_features/press_releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results/article_6c37d259-e9e0-561c-b2c4-db3489058cb5.html", "source_name": "Aspen Daily News", "published_at": "2026-07-09T19:40:08", "published_display": "09 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine's July 30 earnings call is scheduled for 4:30 p.m. ET", "summary": "Neurocrine Biosciences (Nasdaq: NBIX) will release its second-quarter 2026 financial results on July 30, 2026, followed by a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET). The company noted that past similar announcements have typically coincided with small positive ", "url": "https://www.stocktitan.net/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-95wv3r83n05t.html", "source_name": "Stock Titan", "published_at": "2026-07-09T19:39:36", "published_display": "09 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Neurocrine Biosciences, Inc. Stocks", "summary": "This article lists various ETFs that include Neurocrine Biosciences, Inc. (1NBIX) stocks in their holdings. The ETFs are sorted by market value and include details such as asset manager, management style, expense ratio, AUM, and price performance. This information aims to help in", "url": "https://www.tradingview.com/symbols/MIL-1NBIX/etfs/", "source_name": "TradingView", "published_at": "2026-07-09T07:39:35", "published_display": "09 Jul 2026 07:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences (NBIX) Stock Looks Fair On Earnings But Pricey Versus Biotechs", "summary": "Neurocrine Biosciences stock, despite a strong five-year run, appears fairly valued on earnings but expensive compared to the broader biotech sector. The company's P/E ratio is higher than industry averages, though it's close to its implied fair P/E, suggesting the market has alr", "url": "https://finance.yahoo.com/healthcare/articles/neurocrine-biosciences-nbix-stock-looks-021409272.html", "source_name": "Market source", "published_at": "2026-07-08T22:14:00", "published_display": "08 Jul 2026 22:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences (NBIX) Could Be 8% Undervalued Following New Phase 2 Study", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxObW9iRmlUVzlmTUZlajFlZUZMeThobElFUUZYSUh0bVByY1dTSnJJcjdObU9oOTk5S0tXaF9sZF9SNUpvakw5TFVfSS1ScnpvQ1RXSURwdkl2VmttUXVHTC03S3VVN29tU3JPSEdRbTVuUDdZR0JhVTc0NFNlRHpXd1JUaEx3bVo5OUhQVmhOQzA1VUJmWWtqV2p0Q0lVOTNFbEE?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider option exercise and 10b5-1 sales at NBIX (NBIX)", "summary": "Ingrid Delaet, an insider at Neurocrine Biosciences (NBIX), executed an option exercise for 14,571 shares on July 7, 2026, which was paid in cash. This transaction was accompanied by earlier, pre-scheduled 10b5-1 sales of 2,261 shares on May 29, 2026, generating $354,321.31. The ", "url": "https://www.stocktitan.net/sec-filings/NBIX/144-neurocrine-biosciences-inc-sec-filing-800b1c5e8642.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:11:02", "published_display": "07 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences stock and its role in neurological treatments", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOS2hKWWZKd1R1REsxSndkN0FSOHh0U3VfUkxIMXNPQmxpY0dpc2QwUVlORGFmWGkyaE04aDhvaHR5X3pSalVWU21qR0l6T3FVRHN2TGJ3V3hSUjdySzRGbUw2ek1IS1JpcXBRalM3Sk96TzNtbjVqMnhYQjB3dHl2UEo3WjRsd1FYbWF6a21XbFZQWGZySi15OWNkV0FsZnlFNUk5dDNrUXlCbXFCUGFFNXhYNzRYdHdCNXRmN3lCTS1JTVRhR3c?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-07T13:30:46+00:00", "published_display": "07 Jul 2026 13:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences stock hits all-time high at 176.1 USD", "summary": "Neurocrine Biosciences Inc. stock has reached an all-time high of 176.1 USD, reflecting a 35.23% increase over the past year and indicating strong investor confidence. The company's market capitalization is now $17.51 billion, with shares trading just 1% below their 52-week high.", "url": "https://www.investing.com/news/company-news/neurocrine-biosciences-stock-hits-alltime-high-at-1761-usd-93CH-4779512", "source_name": "Investing.com", "published_at": "2026-07-07T14:12:42", "published_display": "07 Jul 2026 14:12", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts Neurocrine Biosciences Price Target to $195 From $183, Maintains Outperform Rating", "summary": "RBC Capital has increased its price target for Neurocrine Biosciences (NBIX) to $195, up from the previous $183. The firm has concurrently maintained its Outperform rating on the company's stock. This adjustment reflects RBC Capital's updated outlook on Neurocrine Biosciences.", "url": "https://www.moomoo.com/news/post/72583061/rbc-capital-adjusts-neurocrine-biosciences-price-target-to-195-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T11:12:42", "published_display": "07 Jul 2026 11:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reasons Why Investors Should Consider Betting on Neurocrine Stock", "summary": "Neurocrine Biosciences is presented as a strong investment due to the commercial success of its marketed drugs, Ingrezza and Crenessity, and a robust late-stage neuroscience pipeline with candidates like direclidine and osavampator. The recent acquisition of Soleno Therapeutics, ", "url": "https://www.tradingview.com/news/zacks:1ef433c68094b:0-reasons-why-investors-should-consider-betting-on-neurocrine-stock/", "source_name": "TradingView", "published_at": "2026-07-06T15:09:31", "published_display": "06 Jul 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences, Inc. (NBIX): Analyst Consensus and Growth Potential with a 12% Upside", "summary": "Neurocrine Biosciences (NBIX) shows strong growth potential with a 12.47% potential upside based on analyst projections. The company specializes in neurological, psychiatric, endocrine, and immunological disorders, boasting a $17.52 billion market cap, robust revenue growth, and ", "url": "https://www.directorstalkinterviews.com/neurocrine-biosciences-inc-nbix-analyst-consensus-and-growth-potential-with-a-12-upside/4121255558", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-06T09:09:31", "published_display": "06 Jul 2026 09:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Neurocrine Biosciences, Inc. \u2013 NASDAQ:NBIX", "summary": "This article provides financial information for Neurocrine Biosciences, Inc. (NASDAQ: NBIX), specifically focusing on its enterprise value to EBIT forward. It appears to be a stub or data placeholder from TradingView, offering a snapshot of financial metrics for the biotechnology", "url": "https://www.tradingview.com/symbols/NASDAQ-NBIX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T14:09:32", "published_display": "04 Jul 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NBIX - Neurocrine Biosciences Inc Options", "summary": "This article provides a detailed financial overview of Neurocrine Biosciences Inc. (NBIX), including its market performance, valuation metrics, earnings, sales data, and insider/institutional ownership. It also lists key financial ratios and stock performance across various timef", "url": "https://finviz.com/stock?t=NBIX&p=m&b=1&ty=oc&ov=chain_date&e=2026-11-20", "source_name": "Finviz", "published_at": "2026-07-04T05:09:32", "published_display": "04 Jul 2026 05:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zacks.com featured highlights include Neurocrine Biosciences, MYR Group, Block, Delek US Holdings and Dycom Industries", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZTF1cVJYMEh6VEw5VmNaTDBrRDlpcExjdXNKZGxTeVVneWUwWXV5VmJPMXFtc2NVSXBSU2pORXc1akZTRmdJWjFRWmFwNWI1LWNBcTJFdVRHZFYxM3Y3MWV3ZVpKZDk0YmVzZThqLUVoSkJtTzFBdmtWRU1XTFhoNzR1Um9kNmo2WjJRWjNWWkVvMjlZSlNLWjJMUEtHWTNVWTBIbnRfVWk?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Neurocrine Biosciences (NBIX)'s Index Removal and INGREZZA Momentum Means For Shareholders", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-02T01:53:32+00:00", "published_display": "02 Jul 2026 01:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine tests CRENESSITY in infants and toddlers with rare CAH", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQZlN2VEN0V3haMi1TeFVLUElvWl83OFlTR0g1YWlCbDY0VkJ6SFBBM1Z4OXJDcmN3MENNa0luMnoxdHlhM01oRFZ5OF8weFE5LTJ3ZVhEa2JtY05RNEhIVUVIMGVfdk9wWGdHZFF0ZVNpS29PTDlDY2ZDQzhFUVAyUkJNYnBmTF9jYy1NbGwyRHRvanBzbjQzY09hT2RVUU1XNHhWQWRtdUJUQkc3NUd1ZEYxZjk5TXZockNabQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences (NBIX) Is Up 6.46% in One Week: What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOeGRSOGNFVWVVUU9NdzdpNWJsR29tcmdCSnFtUUJkX0U0OTVHWnhNLXBuQlg4dkFyV04yWGhVQmtXREV4OEVMNG9wT3JWWWhXSXFrb3VPZ0xDX1VhY0l6eGM2c0w0MHFocGRvZV9VVHpNMW1WZFJQaVlYOUZTdDR3LVZUSkpTRHQ3RDNpeXd2eXBLdUNGS3ppaTgtYWVndw?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think \"Yes\"", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxORkZsSUVBMFdnWkV3eVBYMWNmeS1Pa0pXVkRES3JtTTh0S3pxRlh1bnNKMDZVZHphbWFpdzVJTlhlZVBKQkJJcFZrMU94QWFZcS14Y29TcHAxMmd2RUZZTnYyX2U2NUJIOVZ6LW96SkhPbTRMOXVTQXlVczg5VS13LUkxYkxnMzlXMXJXMUJhMFpoQXVoc3VqMUZpRE1RbUVo?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNLVZXYkRWTUNqLTM0czFkRUZMMUFNTHdGVHlpdGcwLUU3WGlOZkp3eW51d0g4ZXNDSDdIVlg4dE5VM1dVVk1zTm5uS2dVM3NScE45NlBycFgyeW45NjZYbFBabXRmNXV5ai1aQ1gyM3lfTE5GemlnV3dtdVp2T1F2M1dUMl9Oam5ERHlIdWRTaGx6YnN0ZjBmQWxVa1U?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNYU9QbEtibGFBUjg0VUNTcnN0WGlBUnU5dEpmZ09DNWg3Sm9zVmM0c2xTbUpqU0M0azVMeVVGYXlsbFJ1RENXSmphM21uOF9ocFVKdWkzTkl5U28xMS16M2dvb2tiT25GUmtUSlhULXo0dVBLSnhFWTctdWdJemRzakZVcFcxTGxhNktHRWZZUXhicEVwN3BTS2tidEktSng4MDd4aUx2NHBVbGtvSUpxam9n?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences shares jump on fresh long-term CRENESSITY data catalyst | NBIX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNNXNoeXRSeV9sMVhFeVF1Z1pJUEo3MkFUUnNVcG50QzFZaS1hLUpyblBfaTRPaE9lSmZybTRTeHlrRmthai1MNWtpcjZQclA2eEJxcUtIZWhmVTNEYU03NUJpaU4yU1VBLXlGOUNxd3c4X083YnltOVBXbzFuaHVhOENpcHJtMzgzelV0Wk5SWkVYVXUzQVNTc3l6Si00NVFRNWRTM280N3AydHA5dG9BNA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences: $2.9 Billion Soleno Therapeutics Acquisition Expands Rare Disease Portfolio", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNNl9HQkJxcDZCN3lTLWVnZVpaWUFmM2MyUWtJaFZyNFpNa1RZcVlRWnBNM0w5VWpUM0pzMHFDT2pvNHM0Z0VkWkJuV3ZhMHZrZlY0bmtyTXdUYkszVjFINzZ6RXAwOE1CYjZ2czFLOVVJLWVac3FyQ1pIR0hvWldNUExEYVJ5NHFjSmg0VXh2RjRwTHluVFRUNllWQUVIalJKYWhmRmwxV0dRRFFUQjBoTVVYSy1xc2pG0gG-AUFVX3lxTE55V3VTck9tMUZFVUctSEVKVWlJUUtOUF9ycHdiVU1icDdDVzNGOWlGT3JzbzNPdU5yTGlRWDVwZGkzRktiUDFDcm0xcUo2YUNFNkF5ejRlejdkT3QwVVVTWHBVdVlJM1dJUGRtRUl3dzVaenduMDM0dVpSWTY3Q1RyOXNmRG8zdWxBTzNUU1I5R05vS2pCaHRjWUYwcEExOFZNalJaREUzVHpPckY4aS1JeWZjenJlYUJyRFduMVE?oc=5", "source_name": "Pulse 2.0", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences, Inc. Just Recorded A 61% EPS Beat: Here's What Analysts Are Forecasting Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences stock (US62886E1082): Analysts lift price targets after strong Q1 2026 result", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPYnBBQXI4dXI0NHdlbTRaQ09LdWd5Wi1GYVdCSHdRWU11eVJObFlwZTc2LVVHOWliOGZ2VGZhTHl5eWZBS0VuTDZzNTllTEpNSjhUcWZJaHB6X1Y0S3VlbV95NUZFaWNOMXVrQlM2cThVTW1yR0M0NjZpQkdCZEdSM2tNZ1hpN3F2X0puRk94Qkw1b1A0c2dvR09WOENuU2ZEd01DcnJvMjVuUU5Nbm9reHgyOWVkN0kzOThnZF9OeUhyWFFCWjdZ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences (NBIX) Earnings Surge Challenges Cautious Narratives On Margin Durability", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Neurocrine Biosciences (NBIX) After Its Recent Share Price Pullback?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQTjdPYWEwczU0Skt3QkR5clZrNGJRb0kwaV9MS2pOaXpqVnhZaXpDVlAxbmpRSTFrZGZpUUhNQjdKZnJtQUF4Q0gwMk5tTUdlc3hta1ZPeUFJSThvT3ZCRlZOZ2I4THVfMDBQbm1NZkxfN1RLZzJZQ0hQNzRncEVYVDJ4clpIbHdTU2hvVDNFWE5La1FxNnZZZWphUUFOMVhOYlpuVEpLc250UQ?oc=5", "source_name": "Market source", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOQjJqRnVfMVdLTFhGQV9yaEZZcmJteXZHTnMtdlhuRkNRcnJEdTZlUVdvdlZUemJNQ1M0NEM0VDRrQ0x1NXpnZjJ1M3g4VTNsZ0tKTU1wQy01SFJyYkRMOVJwNzFpdTBrQ0txcll0ZWhCZlhlQUFVTUpyODUxcFRzbG1WSVZrdFMweFJGendSTUpLMUcxTFYxMDktbWo4NDFvVlREWklOVlpHdmtkeGIxSjhwZGJDZTdiTFR5dFRJUTlKWXpQZE1rTmlkYjF2RXUtelc5aDBfdjNIRVRYVkx3OXB1emZRdUE?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNYS1MNWNIRDduWnVvSHNjdUdCNFJPM2RwVWZsYUotLXNLUWw3eHpyanRpdVZSRG5ic2ZpdUd6YUtxeEhNWWNyVkV6ZUlxMjNVNHdJSVFwSlFRUmw3ZGtiYm93ZWhlaW80YndpOExpRE53TXdVWkxFSDZGX2Uwc25wemtpanpXaXlReUF0aGdCUnczWkdySFRJMHY0QmhLM192U0JESlJJYXZrRzVScVhQeWVPdmg3M19ObHhCUk1VR3VkaEhWaXdoTEg3bzZRMzhyQ2ZZ?oc=5", "source_name": "Proactive financial news", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and Ball", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxQVmNmU1ZxR3NqRTJyaWRyZ2xRdmh6LUVSYTgwa3I2MGRzQmZ2TC01WVZuRE9ZcWg2YmozUFZrWkRIdVpZeFpGRkdVaVBBam9QcS01eVN2OVpzRVRrZ3duM2FfTVA2Yk1zUUg4cVhpNlIxdEZMUVRXQlpmaEl3ZzlmeFphTFUwa2JzSFFJTFhSY0M4b1VBZmFxR01Bd0YxUDFiVWEzbm9VcjNkcTBwbDcwS0NmZ2dVSGMyeFY0UkhvaUVCM2hDT3RObXM3VHRaay05Z2ZzajJ3ZG9LRlNYTTQ1cmdISTJIQTBoaHJrV2oxXzQtZw?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-16T09:26:25+00:00", "published_display": "16 Jul 2026 09:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences (NASDAQ:NBIX) Fits the Growth at a Reasonable Price Mold of Peter Lynch Screening", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxNcjB5TkN6czEtZUtJcWhydlRPaWlpVklUUnI2ZmpDclFGejVhR3BYRnhpZDhWWkMxeTNhOV9TQzRfREZxcEdoeGtWcVFNZmtwR25zdERjXzRHWTVMZ2pKcXB6bTgyS0NCcWQ3SGpIUHkxTjlQWHRVb0Qzc0NXZTJEMnNsVU9EWG5WcXl1Y3NPcExSLXNfVnhsTmxzS1BmbG5jcVZyakttUDNsNDhmaDJQTzNhRGptcTdxN0RpWE84TWhOTjdyLWctZVdwcHo0X1dCNXZOLVUtSEdFMWpRRVdEM2NBellqam1h?oc=5", "source_name": "ChartMill", "published_at": "2026-07-16T09:00:29+00:00", "published_display": "16 Jul 2026 09:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Securities Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $199", "summary": "BofA Securities has reiterated its Buy rating on Neurocrine Biosciences (NBIX.US) and set a price target of $199. This indicates a positive outlook from the analyst firm regarding the company's future stock performance.", "url": "https://www.moomoo.com/news/post/73008003/bofa-securities-maintains-neurocrine-biosciences-nbixus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-07-16T06:41:37", "published_display": "16 Jul 2026 06:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Neurocrine (NBIX) Run Higher on Rising Earnings Estimates?", "summary": "Neurocrine Biosciences (NBIX) shows strong potential for continued stock growth due to its remarkably improving earnings outlook. Analysts are consistently raising earnings estimates for the biopharmaceutical company, indicating growing optimism. This positive trend in revisions,", "url": "https://finance.yahoo.com/markets/stocks/articles/neurocrine-nbix-run-higher-rising-162002030.html", "source_name": "Market source", "published_at": "2026-07-14T16:13:39", "published_display": "14 Jul 2026 16:13", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Neurocrine Biosciences Inc For: 13 July By Investing.com", "summary": "This article from Investing.com is a standard Form 4 filing for Neurocrine Biosciences Inc (NBIX) as of July 13. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders.", "url": "https://ng.investing.com/news/stock-market-news/form-4-neurocrine-biosciences-inc-for-13-july-93CH-2597537", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T01:11:10", "published_display": "14 Jul 2026 01:11", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences chief legal officer sells $1.79m in stock By Investing.com", "summary": "Darin Lippoldt, Chief Legal Officer at Neurocrine Biosciences (NASDAQ:NBIX), sold 10,000 shares for $1.79 million and simultaneously acquired 10,000 shares for $814,900 through option exercise on July 9, 2026. This transaction occurred while the stock was near its 52-week high, a", "url": "https://ng.investing.com/news/stock-market-news/neurocrine-biosciences-chief-legal-officer-sells-179m-in-stock-93CH-2597515", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T21:32:00", "published_display": "13 Jul 2026 21:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity", "summary": "Neurocrine Biosciences Inc.'s Chief Legal Officer, Darin Lippoldt, reported an open-market sale of 10,000 shares of common stock at a weighted average price of $179.6014 per share, executed under a pre-arranged Rule 10b5-1 trading plan. On the same day, Lippoldt exercised non-qua", "url": "https://www.stocktitan.net/sec-filings/NBIX/form-4-neurocrine-biosciences-inc-insider-trading-activity-d9d7f3ed5f97.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:11:10", "published_display": "13 Jul 2026 21:11", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences chief legal officer sells $1.79m in stock", "summary": "Darin Lippoldt, Chief Legal Officer at Neurocrine Biosciences, sold 10,000 shares of common stock for $1.79 million on July 9, 2026, through a pre-planned trading arrangement, while the stock trades near its 52-week high. Prior to this sale, Lippoldt acquired 10,000 shares by exe", "url": "https://www.investing.com/news/insider-trading-news/neurocrine-biosciences-chief-legal-officer-sells-179m-in-stock-93CH-4789271", "source_name": "Investing.com", "published_at": "2026-07-13T20:13:39", "published_display": "13 Jul 2026 20:13", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences (NBIX) officer exercises options, sells 4,367 shares", "summary": "Neurocrine Biosciences' Chief Regulatory Officer, Ingrid Delaet, executed an options exercise and stock sale. She acquired 4,367 shares at $106.02 per share and simultaneously sold them at an average price of $181.02 per share through a pre-arranged Rule 10b5-1 trading plan. Foll", "url": "https://www.stocktitan.net/sec-filings/NBIX/form-4-neurocrine-biosciences-inc-insider-trading-activity-0c1848f39ffd.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:11:10", "published_display": "13 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist raises Neurocrine Bio stock price target on pipeline potential", "summary": "Truist Securities has increased its price target for Neurocrine Biosciences Inc. (NASDAQ: NBIX) shares to $200 from $155, maintaining a Buy rating, due to strong pipeline potential and expected Q2 2026 results beating expectations. The firm anticipates a fiscal year 2026 guidance", "url": "https://www.investing.com/news/analyst-ratings/truist-raises-neurocrine-bio-stock-price-target-on-pipeline-potential-93CH-4788462", "source_name": "Investing.com", "published_at": "2026-07-13T12:41:50", "published_display": "13 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Lifts Price Target on Neurocrine Biosciences to $185 From $176, Keeps Outperform Rating", "summary": "Wedbush has increased its price target for Neurocrine Biosciences (NBIX) shares to $185 from $176, while maintaining an Outperform rating. This adjustment reflects Wedbush's continued positive outlook on the company's prospects.", "url": "https://www.moomoo.com/news/post/72858445/wedbush-lifts-price-target-on-neurocrine-biosciences-to-185-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T12:11:10", "published_display": "13 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences Inc (NASDAQ:NBIX) Scores High in Affordable Growth Screen", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxORVNkaGx2VWJCUU01YmRXcGk1SVVLelNLSmxiU25SUUJfQWpFbDRYZ1VsYUZ4SDBXSFdOYVlubk1LT0F1UnU4Wm8zaHlCY29TUnktM09tR2MyY1JPaFpQRWd6R2RDTGdGUDliZkgyQThOa3F2a2Q2TVcwUXhONC0tNGp3VkFveTJmcE9CdXVGMUZoZVNXNUJnXzdlSW83ZWthYlEwdmg0LU83dDV4LVRNU3l3d1lJSnBveVVsT3c0WkJKNTcwNkkxWQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T09:20:27+00:00", "published_display": "11 Jul 2026 09:20", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences (NBIX) Posts Strong Q1 Results, Is More Upside Still Left?", "summary": "Neurocrine Biosciences (NBIX) reported strong Q1 2026 results with over US$800 million in net product sales, driven by INGREZZA, leading to significant institutional interest and a 37.41% share price return over 90 days. Despite this surge, Simply Wall St's narrative valuation su", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/neurocrine-biosciences-nbix-posts-strong-q1-results-is-more", "source_name": "Simply Wall Street", "published_at": "2026-07-11T08:11:10", "published_display": "11 Jul 2026 08:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEUROCRINE BIOSCIENCES INC (NBIX) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTFB4TWdGYmo5N01lVF9hc2tfcXFpWkNQZjExcXpxNGZyT0JJeHpEbF9GYnVIbjY0SmVsOVptSWNxSFduMHJJQy1CRzVfcFVrRE0wYW1zLXdPcWNlR1QxeWVSS0g2dEQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T00:20:41+00:00", "published_display": "11 Jul 2026 00:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] NEUROCRINE BIOSCIENCES INC SEC Filing", "summary": "Neurocrine Biosciences (NBIX) filed a Form 144 indicating an affiliate plans to sell 4,367 shares of common stock on 07/10/2026, valued at $788,461.85, connected to the exercise of stock options. This filing also details prior Rule 10b5-1 sales by Ingrid Delaet, including 8,433 s", "url": "https://www.stocktitan.net/sec-filings/NBIX/144-neurocrine-biosciences-inc-sec-filing-299576120862.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:41:03", "published_display": "10 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences Insider Sold Shares Worth $2,603,112, According to a Recent SEC Filing", "summary": "An insider at Neurocrine Biosciences recently sold shares totaling $2,603,112. This transaction was disclosed in a recent SEC filing, indicating significant insider selling activity.", "url": "https://www.moomoo.com/news/post/72764814/neurocrine-biosciences-insider-sold-shares-worth-2603112-according-to-a?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-10T19:39:21", "published_display": "10 Jul 2026 19:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNV1hvazEtOEtkeGFjQTN3Q0ZIcTJScV9lX0FqUk1aQVVrWjhXdXZiWFFlaXVSMVJpQnZPcksxQkE3azVDN0hsdDRobFF4dmxTRkw0U1F0U2lXd1M3MlVuQTVGMGxZOVhIcFJTeWRIRTIwT2tmQ1VfVHl4OUN4OWxTRFBHbDhGLUpzd2xKOFhfY3Z0VGtzVXdLQnQ1QQ?oc=5", "source_name": "Market source", "published_at": "2026-07-10T16:45:02+00:00", "published_display": "10 Jul 2026 16:45", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/neurocrine-shares-hit-highs-sales-155848153.html", "source_name": "FX Empire", "published_at": "2026-07-10T15:58:48+00:00", "published_display": "10 Jul 2026 15:58", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences (NBIX) Stock Looks Reasonable After Its 90% Run", "summary": "After a significant 90% return over the past five years, Neurocrine Biosciences (NBIX) appears to be trading near its fair value rather than offering a clear bargain. The stock's current P/E ratio of 26.8x is higher than the biotech industry average but aligns closely with its ta", "url": "https://www.sahmcapital.com/news/content/neurocrine-biosciences-nbix-stock-looks-reasonable-after-its-90-run-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T06:41:03", "published_display": "10 Jul 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Neurocrine\u2019s (NBIX) CRENESSITY Push Into Infants Just Recast Its Rare-Disease Strategy?", "summary": "Neurocrine Biosciences has launched a Phase 2 study for CRENESSITY in infants, signaling a strategic push into younger pediatric patients with congenital adrenal hyperplasia, a group with no approved therapies. While this move could broaden CRENESSITY\u2019s market, the company's fina", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbix/neurocrine-biosciences/news/did-neurocrines-nbix-crenessity-push-into-infants-just-recas/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-10T02:39:36", "published_display": "10 Jul 2026 02:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences chief regulatory officer sells $2.6m stock By Investing.com", "summary": "Ingrid Delaet, Chief Regulatory Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), sold approximately $2.6 million worth of common stock between July 7 and July 9, 2026, following the exercise of stock options. The sales were conducted through a Rule 10b5-1 trading plan, with ", "url": "https://ca.investing.com/news/stock-market-news/neurocrine-biosciences-chief-regulatory-officer-sells-26m-stock-93CH-4728313", "source_name": "Investing.com Canada", "published_at": "2026-07-09T22:39:36", "published_display": "09 Jul 2026 22:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Neurocrine Biosciences Inc For: 9 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Neurocrine Biosciences Inc. with the filing date of July 9. Form 4s are SEC filings used to report changes in beneficial ownership of securities by company insiders. The article notes that Neurocrine Biosciences Inc. ", "url": "https://ca.investing.com/news/stock-market-news/form-4-neurocrine-biosciences-inc-for-9-july-93CH-4728315", "source_name": "Investing.com Canada", "published_at": "2026-07-09T22:39:35", "published_display": "09 Jul 2026 22:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine (NBIX) officer sells 14,571 shares under Rule 10b5-1 plan", "summary": "Ingrid Delaet, Neurocrine Biosciences' Chief Regulatory Officer, exercised stock options for 14,571 shares and subsequently sold them in open-market transactions between July 7-9, 2026. The sales, executed under a pre-arranged Rule 10b5-1 trading plan, netted approximately $2.60 ", "url": "https://www.stocktitan.net/sec-filings/NBIX/form-4-neurocrine-biosciences-inc-insider-trading-activity-ad93694159b9.html", "source_name": "Stock Titan", "published_at": "2026-07-09T22:39:35", "published_display": "09 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results", "summary": "Neurocrine Biosciences, Inc. announced its second quarter 2026 financial results conference call and webcast will take place on July 30, 2026, at 1:30 p.m. Pacific Time. The press release will be issued at 1:00 p.m. PT on the same day. Details for dial-in and webcast access are p", "url": "https://www.aspendailynews.com/online_features/press_releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results/article_6c37d259-e9e0-561c-b2c4-db3489058cb5.html", "source_name": "Aspen Daily News", "published_at": "2026-07-09T19:40:08", "published_display": "09 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine's July 30 earnings call is scheduled for 4:30 p.m. ET", "summary": "Neurocrine Biosciences (Nasdaq: NBIX) will release its second-quarter 2026 financial results on July 30, 2026, followed by a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET). The company noted that past similar announcements have typically coincided with small positive ", "url": "https://www.stocktitan.net/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-95wv3r83n05t.html", "source_name": "Stock Titan", "published_at": "2026-07-09T19:39:36", "published_display": "09 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Neurocrine Biosciences, Inc. Stocks", "summary": "This article lists various ETFs that include Neurocrine Biosciences, Inc. (1NBIX) stocks in their holdings. The ETFs are sorted by market value and include details such as asset manager, management style, expense ratio, AUM, and price performance. This information aims to help in", "url": "https://www.tradingview.com/symbols/MIL-1NBIX/etfs/", "source_name": "TradingView", "published_at": "2026-07-09T07:39:35", "published_display": "09 Jul 2026 07:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences (NBIX) Stock Looks Fair On Earnings But Pricey Versus Biotechs", "summary": "Neurocrine Biosciences stock, despite a strong five-year run, appears fairly valued on earnings but expensive compared to the broader biotech sector. The company's P/E ratio is higher than industry averages, though it's close to its implied fair P/E, suggesting the market has alr", "url": "https://finance.yahoo.com/healthcare/articles/neurocrine-biosciences-nbix-stock-looks-021409272.html", "source_name": "Market source", "published_at": "2026-07-08T22:14:00", "published_display": "08 Jul 2026 22:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences (NBIX) Could Be 8% Undervalued Following New Phase 2 Study", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxObW9iRmlUVzlmTUZlajFlZUZMeThobElFUUZYSUh0bVByY1dTSnJJcjdObU9oOTk5S0tXaF9sZF9SNUpvakw5TFVfSS1ScnpvQ1RXSURwdkl2VmttUXVHTC03S3VVN29tU3JPSEdRbTVuUDdZR0JhVTc0NFNlRHpXd1JUaEx3bVo5OUhQVmhOQzA1VUJmWWtqV2p0Q0lVOTNFbEE?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider option exercise and 10b5-1 sales at NBIX (NBIX)", "summary": "Ingrid Delaet, an insider at Neurocrine Biosciences (NBIX), executed an option exercise for 14,571 shares on July 7, 2026, which was paid in cash. This transaction was accompanied by earlier, pre-scheduled 10b5-1 sales of 2,261 shares on May 29, 2026, generating $354,321.31. The ", "url": "https://www.stocktitan.net/sec-filings/NBIX/144-neurocrine-biosciences-inc-sec-filing-800b1c5e8642.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:11:02", "published_display": "07 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences stock and its role in neurological treatments", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOS2hKWWZKd1R1REsxSndkN0FSOHh0U3VfUkxIMXNPQmxpY0dpc2QwUVlORGFmWGkyaE04aDhvaHR5X3pSalVWU21qR0l6T3FVRHN2TGJ3V3hSUjdySzRGbUw2ek1IS1JpcXBRalM3Sk96TzNtbjVqMnhYQjB3dHl2UEo3WjRsd1FYbWF6a21XbFZQWGZySi15OWNkV0FsZnlFNUk5dDNrUXlCbXFCUGFFNXhYNzRYdHdCNXRmN3lCTS1JTVRhR3c?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-07T13:30:46+00:00", "published_display": "07 Jul 2026 13:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences stock hits all-time high at 176.1 USD", "summary": "Neurocrine Biosciences Inc. stock has reached an all-time high of 176.1 USD, reflecting a 35.23% increase over the past year and indicating strong investor confidence. The company's market capitalization is now $17.51 billion, with shares trading just 1% below their 52-week high.", "url": "https://www.investing.com/news/company-news/neurocrine-biosciences-stock-hits-alltime-high-at-1761-usd-93CH-4779512", "source_name": "Investing.com", "published_at": "2026-07-07T14:12:42", "published_display": "07 Jul 2026 14:12", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts Neurocrine Biosciences Price Target to $195 From $183, Maintains Outperform Rating", "summary": "RBC Capital has increased its price target for Neurocrine Biosciences (NBIX) to $195, up from the previous $183. The firm has concurrently maintained its Outperform rating on the company's stock. This adjustment reflects RBC Capital's updated outlook on Neurocrine Biosciences.", "url": "https://www.moomoo.com/news/post/72583061/rbc-capital-adjusts-neurocrine-biosciences-price-target-to-195-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T11:12:42", "published_display": "07 Jul 2026 11:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reasons Why Investors Should Consider Betting on Neurocrine Stock", "summary": "Neurocrine Biosciences is presented as a strong investment due to the commercial success of its marketed drugs, Ingrezza and Crenessity, and a robust late-stage neuroscience pipeline with candidates like direclidine and osavampator. The recent acquisition of Soleno Therapeutics, ", "url": "https://www.tradingview.com/news/zacks:1ef433c68094b:0-reasons-why-investors-should-consider-betting-on-neurocrine-stock/", "source_name": "TradingView", "published_at": "2026-07-06T15:09:31", "published_display": "06 Jul 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences, Inc. (NBIX): Analyst Consensus and Growth Potential with a 12% Upside", "summary": "Neurocrine Biosciences (NBIX) shows strong growth potential with a 12.47% potential upside based on analyst projections. The company specializes in neurological, psychiatric, endocrine, and immunological disorders, boasting a $17.52 billion market cap, robust revenue growth, and ", "url": "https://www.directorstalkinterviews.com/neurocrine-biosciences-inc-nbix-analyst-consensus-and-growth-potential-with-a-12-upside/4121255558", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-06T09:09:31", "published_display": "06 Jul 2026 09:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Neurocrine Biosciences, Inc. \u2013 NASDAQ:NBIX", "summary": "This article provides financial information for Neurocrine Biosciences, Inc. (NASDAQ: NBIX), specifically focusing on its enterprise value to EBIT forward. It appears to be a stub or data placeholder from TradingView, offering a snapshot of financial metrics for the biotechnology", "url": "https://www.tradingview.com/symbols/NASDAQ-NBIX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T14:09:32", "published_display": "04 Jul 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NBIX - Neurocrine Biosciences Inc Options", "summary": "This article provides a detailed financial overview of Neurocrine Biosciences Inc. (NBIX), including its market performance, valuation metrics, earnings, sales data, and insider/institutional ownership. It also lists key financial ratios and stock performance across various timef", "url": "https://finviz.com/stock?t=NBIX&p=m&b=1&ty=oc&ov=chain_date&e=2026-11-20", "source_name": "Finviz", "published_at": "2026-07-04T05:09:32", "published_display": "04 Jul 2026 05:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zacks.com featured highlights include Neurocrine Biosciences, MYR Group, Block, Delek US Holdings and Dycom Industries", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZTF1cVJYMEh6VEw5VmNaTDBrRDlpcExjdXNKZGxTeVVneWUwWXV5VmJPMXFtc2NVSXBSU2pORXc1akZTRmdJWjFRWmFwNWI1LWNBcTJFdVRHZFYxM3Y3MWV3ZVpKZDk0YmVzZThqLUVoSkJtTzFBdmtWRU1XTFhoNzR1Um9kNmo2WjJRWjNWWkVvMjlZSlNLWjJMUEtHWTNVWTBIbnRfVWk?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Neurocrine Biosciences (NBIX)'s Index Removal and INGREZZA Momentum Means For Shareholders", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-02T01:53:32+00:00", "published_display": "02 Jul 2026 01:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine tests CRENESSITY in infants and toddlers with rare CAH", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQZlN2VEN0V3haMi1TeFVLUElvWl83OFlTR0g1YWlCbDY0VkJ6SFBBM1Z4OXJDcmN3MENNa0luMnoxdHlhM01oRFZ5OF8weFE5LTJ3ZVhEa2JtY05RNEhIVUVIMGVfdk9wWGdHZFF0ZVNpS29PTDlDY2ZDQzhFUVAyUkJNYnBmTF9jYy1NbGwyRHRvanBzbjQzY09hT2RVUU1XNHhWQWRtdUJUQkc3NUd1ZEYxZjk5TXZockNabQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences (NBIX) Is Up 6.46% in One Week: What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOeGRSOGNFVWVVUU9NdzdpNWJsR29tcmdCSnFtUUJkX0U0OTVHWnhNLXBuQlg4dkFyV04yWGhVQmtXREV4OEVMNG9wT3JWWWhXSXFrb3VPZ0xDX1VhY0l6eGM2c0w0MHFocGRvZV9VVHpNMW1WZFJQaVlYOUZTdDR3LVZUSkpTRHQ3RDNpeXd2eXBLdUNGS3ppaTgtYWVndw?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think \"Yes\"", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxORkZsSUVBMFdnWkV3eVBYMWNmeS1Pa0pXVkRES3JtTTh0S3pxRlh1bnNKMDZVZHphbWFpdzVJTlhlZVBKQkJJcFZrMU94QWFZcS14Y29TcHAxMmd2RUZZTnYyX2U2NUJIOVZ6LW96SkhPbTRMOXVTQXlVczg5VS13LUkxYkxnMzlXMXJXMUJhMFpoQXVoc3VqMUZpRE1RbUVo?oc=5", "source_name": "Market source", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNLVZXYkRWTUNqLTM0czFkRUZMMUFNTHdGVHlpdGcwLUU3WGlOZkp3eW51d0g4ZXNDSDdIVlg4dE5VM1dVVk1zTm5uS2dVM3NScE45NlBycFgyeW45NjZYbFBabXRmNXV5ai1aQ1gyM3lfTE5GemlnV3dtdVp2T1F2M1dUMl9Oam5ERHlIdWRTaGx6YnN0ZjBmQWxVa1U?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNYU9QbEtibGFBUjg0VUNTcnN0WGlBUnU5dEpmZ09DNWg3Sm9zVmM0c2xTbUpqU0M0azVMeVVGYXlsbFJ1RENXSmphM21uOF9ocFVKdWkzTkl5U28xMS16M2dvb2tiT25GUmtUSlhULXo0dVBLSnhFWTctdWdJemRzakZVcFcxTGxhNktHRWZZUXhicEVwN3BTS2tidEktSng4MDd4aUx2NHBVbGtvSUpxam9n?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences shares jump on fresh long-term CRENESSITY data catalyst | NBIX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNNXNoeXRSeV9sMVhFeVF1Z1pJUEo3MkFUUnNVcG50QzFZaS1hLUpyblBfaTRPaE9lSmZybTRTeHlrRmthai1MNWtpcjZQclA2eEJxcUtIZWhmVTNEYU03NUJpaU4yU1VBLXlGOUNxd3c4X083YnltOVBXbzFuaHVhOENpcHJtMzgzelV0Wk5SWkVYVXUzQVNTc3l6Si00NVFRNWRTM280N3AydHA5dG9BNA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences: $2.9 Billion Soleno Therapeutics Acquisition Expands Rare Disease Portfolio", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNNl9HQkJxcDZCN3lTLWVnZVpaWUFmM2MyUWtJaFZyNFpNa1RZcVlRWnBNM0w5VWpUM0pzMHFDT2pvNHM0Z0VkWkJuV3ZhMHZrZlY0bmtyTXdUYkszVjFINzZ6RXAwOE1CYjZ2czFLOVVJLWVac3FyQ1pIR0hvWldNUExEYVJ5NHFjSmg0VXh2RjRwTHluVFRUNllWQUVIalJKYWhmRmwxV0dRRFFUQjBoTVVYSy1xc2pG0gG-AUFVX3lxTE55V3VTck9tMUZFVUctSEVKVWlJUUtOUF9ycHdiVU1icDdDVzNGOWlGT3JzbzNPdU5yTGlRWDVwZGkzRktiUDFDcm0xcUo2YUNFNkF5ejRlejdkT3QwVVVTWHBVdVlJM1dJUGRtRUl3dzVaenduMDM0dVpSWTY3Q1RyOXNmRG8zdWxBTzNUU1I5R05vS2pCaHRjWUYwcEExOFZNalJaREUzVHpPckY4aS1JeWZjenJlYUJyRFduMVE?oc=5", "source_name": "Pulse 2.0", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences, Inc. Just Recorded A 61% EPS Beat: Here's What Analysts Are Forecasting Next", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxNTHdSU3lrcWtQaXlnbkJXRnBnbnFmcGdqRnVSNlZMNEFYY25UQWRuaWR2VUdYdVpLTzNqY3ItaW5qZjhxeF9xU1VGUEdmRlVGNERnWkt5bXdVYVg5NEdWNXNDcmpnZF8wdEVPWDdTaUVLNEY0RzdqcEM5ZDJiblBrU25MTDFRUFp1STNpWFk2eEd2V0E0SU9kUmR1R29PdmJ3Z29FRFNUVmhSWF9lSE5PTk9OTFlZa1E0LWN2Q2I0ZmJ0UWE4OU95ZnRNY3dCeXRHeUgwRHM2b1E1dlo5ODZ6Wmk3eFlMSzd6VnRyNdIB8gFBVV95cUxQS0lreXFkeFM3cUdsbDg3OHZWeG5iaFpUemxWQ182NkpmTXZqLW9KSVNzd2dwcnhUWk9qSVBlak42QVpkczJKWlhzTW9GSHRTbUloZlJZVWxOeFRfT2lLeEhFRUxlaFlsb2l2UlAxLVlzTEh0a0pxVk1GbVp5QmZjeVFjMTJ1bkx5UjA1TlYxc0MzMW1Jdzc4aW81RzRhSk9JTUQ5TDItNm15UjB6UHpFcE5DV0gwcGpweVRoQnZla1Jfb1dhczg4T0x4b3lFSUowbWI1cmhoS3dZVGdsamtYNXpjdThmLXlzejd0cnc1ajlFUQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences stock (US62886E1082): Analysts lift price targets after strong Q1 2026 result", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPYnBBQXI4dXI0NHdlbTRaQ09LdWd5Wi1GYVdCSHdRWU11eVJObFlwZTc2LVVHOWliOGZ2VGZhTHl5eWZBS0VuTDZzNTllTEpNSjhUcWZJaHB6X1Y0S3VlbV95NUZFaWNOMXVrQlM2cThVTW1yR0M0NjZpQkdCZEdSM2tNZ1hpN3F2X0puRk94Qkw1b1A0c2dvR09WOENuU2ZEd01DcnJvMjVuUU5Nbm9reHgyOWVkN0kzOThnZF9OeUhyWFFCWjdZ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences (NBIX) Earnings Surge Challenges Cautious Narratives On Margin Durability", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Neurocrine Biosciences (NBIX) After Its Recent Share Price Pullback?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQTjdPYWEwczU0Skt3QkR5clZrNGJRb0kwaV9MS2pOaXpqVnhZaXpDVlAxbmpRSTFrZGZpUUhNQjdKZnJtQUF4Q0gwMk5tTUdlc3hta1ZPeUFJSThvT3ZCRlZOZ2I4THVfMDBQbm1NZkxfN1RLZzJZQ0hQNzRncEVYVDJ4clpIbHdTU2hvVDNFWE5La1FxNnZZZWphUUFOMVhOYlpuVEpLc250UQ?oc=5", "source_name": "Market source", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOQjJqRnVfMVdLTFhGQV9yaEZZcmJteXZHTnMtdlhuRkNRcnJEdTZlUVdvdlZUemJNQ1M0NEM0VDRrQ0x1NXpnZjJ1M3g4VTNsZ0tKTU1wQy01SFJyYkRMOVJwNzFpdTBrQ0txcll0ZWhCZlhlQUFVTUpyODUxcFRzbG1WSVZrdFMweFJGendSTUpLMUcxTFYxMDktbWo4NDFvVlREWklOVlpHdmtkeGIxSjhwZGJDZTdiTFR5dFRJUTlKWXpQZE1rTmlkYjF2RXUtelc5aDBfdjNIRVRYVkx3OXB1emZRdUE?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNYS1MNWNIRDduWnVvSHNjdUdCNFJPM2RwVWZsYUotLXNLUWw3eHpyanRpdVZSRG5ic2ZpdUd6YUtxeEhNWWNyVkV6ZUlxMjNVNHdJSVFwSlFRUmw3ZGtiYm93ZWhlaW80YndpOExpRE53TXdVWkxFSDZGX2Uwc25wemtpanpXaXlReUF0aGdCUnczWkdySFRJMHY0QmhLM192U0JESlJJYXZrRzVScVhQeWVPdmg3M19ObHhCUk1VR3VkaEhWaXdoTEg3bzZRMzhyQ2ZZ?oc=5", "source_name": "Proactive financial news", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 87, "total_relevant": 51, "sentiment_summary": {"positive": 24, "negative": 3, "neutral": 24, "score": 58, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 16.5, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 4.95, "count": 9}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 24, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 177.11, "latest_week": "2026-07-10", "one_week_move": 1.6, "four_week_move": 10.9, "twelve_week_move": 32.9, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.210589, "market_dynamics_buy_signal": false, "relative_strength": 7.087936, "fair_value_gap": 35.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 53.371, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.6% over one week, +10.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "Stock Titan", "count": 7}, {"label": "Moomoo", "count": 4}, {"label": "ChartMill", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "TradingView", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Investing.com Nigeria", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 9}, {"label": "Analyst action", "count": 5}, {"label": "Regulatory and legal", "count": 3}, {"label": "Deals and strategy", "count": 3}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+1.6% over one week, +10.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and Ball"}], "updated_at": "2026-07-16T21:18:27.432602+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}